As of 4:00pm ET
| -0.12 / -2.60%|
The 6 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 6.50, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +44.44% increase from the last price of 4.50.
The current consensus among 8 polled investment analysts is to Hold stock in BioCryst Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.